Clinical Research Directory

Inclusion Criteria: * Participants must have confirmed diagnosis of symptomatic MM per IMWG criteria. * Participants must have High-risk myeloma according to IMS/IMWG CGS * Participants must be considered a candidate for high-dose chemotherapy and ASCT, as described in the protocol. * Participants must have measurable disease as defined in the protocol. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (WHO=3 is allowed only if caused by MM and not by co-morbid conditions). * Participants must have clinical laboratory values within a prespecified range. Exclusion Criteria: * Known contraindications to the use of any IMP or axMP or required concomitant drugs or supportive treatment. * known systemic amyloidosis (except for AL amyloidosis of the skin or the bone marrow), POEMS syndrome, Waldenstrom's macroglobulinemia; primary plasma cell leukemia * Administration of systemic therapy for multiple myeloma except osteoprotective therapy. Emergency myeloma treatment with dexamethasone is allowed according to specifications in the protocol. It is allowed to include patients after 1 cycle of any anti-myeloma first-line treatment within the specifications of the protocol * known central nervous system involvement by MM.